Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pauza, M. E.
Right arrow Articles by Lo, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pauza, M. E.
Right arrow Articles by Lo, D.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 48, Issue 10 1948-1953, Copyright © 1999 by American Diabetes Association

ARTICLES

T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes

ME Pauza, H Neal, A Hagenbaugh, H Cheroutre and D Lo
Department of Immunology, The Scripps Research Institute, La Jolla, San Diego, California 92037, USA.

In a number of animal models of spontaneous autoimmune diabetes, pathogenesis has been highly correlated with autoreactive T-cell production of the type 1 cytokine interferon-gamma (IFN-gamma), while protection from disease was associated with type 2 cytokines such as interleukin (IL)-4. Curiously, in some models, diabetes is associated with unexpected cytokine patterns; for example, diabetes can develop in NOD mice lacking a functional IFN-gamma gene. In another situation, acceleration of diabetes occurs in transgenic mice with constitutive beta-cell expression of the type 2 cytokine IL-10. IL-10 has generally been associated with immunosuppression, including the modulation of class II expression on antigen-presenting cells and the generation of regulatory CD4 T-cells. Because it is possible that unregulated expression of any cytokine might lead to unphysiological effects in vivo, we tested the notion that an inducible T-cell-specific IL-10 transgene might yet mediate a more physiological protection from autoimmune diabetes. Our results show that indeed, regulated T-cell production of IL-10 does not accelerate diabetes and instead can provide significant protection from disease. These results help rectify the apparent discrepancies between the effect of IL-10 on various models of autoimmune diabetes.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. S. Smith, T. Patterson, and M. E. Pauza
Transgenic Ly-49A Inhibits Antigen-Driven T Cell Activation and Delays Diabetes
J. Immunol., April 1, 2005; 174(7): 3897 - 3905.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Kommajosyula, S. Reddy, K. Nitschke, J. R. Kanwar, M. Karanam, and G. W. Krissansen
Leukocytes infiltrating the pancreatic islets of nonobese diabetic mice are transformed into inactive exiles by combinational anti-cell adhesion therapy
J. Leukoc. Biol., October 1, 2001; 70(4): 510 - 517.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. E. Pauza, A. Nguyen, T. Wolfe, I-C. Ho, L. H. Glimcher, M. von Herrath, and D. Lo
Variable Effects of Transgenic c-Maf on Autoimmune Diabetes
Diabetes, January 1, 2001; 50(1): 39 - 46.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.